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http://dx.doi.org/10.1016/j.ccr.2014.01.008SUMMARYWe report that two oncogenes coamplified on chromosome 3q26, PRKCI and SOX2, cooperate to drive a
stem-like phenotype in lung squamous cell carcinoma (LSCC). Protein kinase Ci (PKCi) phosphorylates
SOX2, a master transcriptional regulator of stemness, and recruits it to the promoter of Hedgehog (Hh)
acyltransferase (HHAT) that catalyzes the rate-limiting step in Hh ligand production. PKCi-mediated SOX2
phosphorylation is required for HHAT promoter occupancy, HHAT expression, and maintenance of a
stem-like phenotype. Primary LSCC tumors coordinately overexpress PKCi, SOX2, and HHAT and require
PKCi-SOX2-HHAT signaling to maintain a stem-like phenotype. Thus, PKCi and SOX2 are genetically,
biochemically, and functionally linked in LSCC, and together they drive tumorigenesis by establishing a
cell-autonomous Hh signaling axis.INTRODUCTION
Lung cancer is the major cause of cancer death, with a 5-year-
survival rate of 16% (Siegel et al., 2012). Non-small cell lung
cancer (NSCLC) accounts for 80% of lung cancer cases and
is subdivided into adenocarcinoma (LAC), squamous cell
carcinoma (LSCC), and large cell carcinoma (LCLC). Distinct
histologies, genetic and epigenetic changes, and sites of origin
characterize NSCLC subtypes, suggesting they may have
unique responses to therapy. Recent therapies targeting
pathways active in NSCLC subtypes have resulted in encour-
aging new treatments for LAC driven by EGFR or EML4-ALK
mutations. However, few advances have resulted in better
treatment options for LSCC, a carcinoma that accounts for
30% of all lung cancer cases. Thus, there is a need to better un-
derstand molecular mechanisms that drive LSCC and to trans-
late this knowledge into better intervention strategies.
NSCLC tumors contain stem-like cells responsible for lung
tumor initiation, maintenance, relapse, and metastasis (Chen
et al., 2008; Eramo et al., 2008; Justilien et al., 2012). These cells
exhibit resistance to commonly used therapeutic agents (Chen
et al., 2008), making them a likely cause of therapeutic failure.Significance
Lung cancer is the leading cause of cancer deaths worldwide.
acterized by poor therapeutic response, a high relapse rate, an
and functional link between two oncogenes on chromosome
pressed in amajority of LSCC tumors. Our data indicate that ch
vate PRKCI and SOX2 that together establish a PKCi-SOX2-H
results provide a compelling rationale for use of PKCi inhibito
CSimilar cell populations exist in several cancer types (Chen
et al., 2012; Driessens et al., 2012; Schepers et al., 2012). Line-
age tracing reveals these cells clonally expand to give rise to
malignant and nonmalignant, differentiated cell types. These
highly tumorigenic cells exhibit self-renewal by activating devel-
opmental pathways including Wnt, Hedgehog (Hh), and Notch
and by aberrant expression of stem-related genes such as
BMI1 (Siddique and Saleem, 2012), OCT3/4 (Chiou et al.,
2010), SOX2 (Yuan et al., 2010), and NANOG (Chiou et al.,
2010) that participate in their maintenance. As tumorigenic
drivers, these stem-like cells must be effectively targeted to elicit
long-lasting therapeutic responses.
We previously identified PRKCI as an oncogene in LSCC
(Regala et al., 2005b). PRKCI is overexpressed in LSCC cells
and primary tumors due to tumor-specific amplification of a
chromosome 3q26 amplicon (Regala et al., 2005b). Tumor pro-
tein kinase Ci (PKCi) expression is predictive of poor clinical
outcome, and PKCi drives LSCC cell invasion and transformed
growth in vitro and in vivo (Frederick et al., 2008; Justilien and
Fields, 2009; Regala et al., 2005a, 2008). Genetic disruption of
Prkci in the LSL-KrasG12D mouse LAC model blocks tumor initi-
ation by inhibiting expansion of putative lung cancer stem cellsLSCC represents 30% of lung cancer diagnoses and is char-
d poor prognosis. Here, we identify a genetic, biochemical,
3q26, PRKCI and SOX2, that are coamplified and overex-
romosome 3q26 copy number gains serve to genetically acti-
HAT signaling axis that drives a stem-like phenotype. Our
rs currently in clinical development to target LSCC.
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Figure 1. Lung Cancer Oncospheres Exhibit Stem-like Characteristics
(A) Phase contrast photomicrographs of H1703, ChagoK1, and H1299 parental adherent cells (top), oncospheres in low-adherence culture (middle), and
redifferentiated oncosphere cells after return to adherent culture (bottom).
(B) qPCR for putative stem cell markers expressed as fold of parental cells ± SEM, n = 3; *p < 0.05 versus NT adherent cells. Results are representative of five
independent experiments.
(C) Photomicrographs showing clonal expansion of individual cells into oncospheres over a 15 day period.
(D) Anchorage-independent growth expressed as mean fold-change from parental cells ± SEM, n = 5, *p < 0.05 versus NT adherent cells. Results are repre-
sentative of five independent experiments.
(E) Formation of lung orthotopic tumors in immunocompromisedmice. Ten thousand parental H1299 adherent or oncosphere cells were implanted into the lungs
of immune-deficient mice. Lateral and dorsal views of bioluminescent images of a tumor-bearingmouse (a) and corresponding bioluminescence image upon lung
dissection (b). Hematoxylin and eosin staining of typical parental and oncosphere tumors (c). Oncospheres develop primary tumors at the site of injection (arrows)
and multiple lesions to the ipsilateral and contralateral lobes of the lung (arrowheads); parental cells develop either a single, small tumor at the site of injection
(legend continued on next page)
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PKCi and SOX2 Maintain Lung Cancer Stem-like Cells(Regala et al., 2009). Here, we demonstrate that PRKCI main-
tains a highly tumorigenic phenotype in lung cancer cells
harboring PRKCI amplification, and in LSCC tumors. Our results
reveal a genetic, biochemical, and functional interaction be-
tween PRKCI and SOX2 that coordinately drives growth and
maintenance of LSCC stem-like cells.
RESULTS
Lung Oncosphere Cells Exhibit Stem-like Properties
Highly malignant tumor cells can be enriched in defined medium
at low adherence (Eramo et al., 2008; Justilien et al., 2012).
These conditions favor growth of highly tumorigenic stem-like
cells, while negatively selecting for less tumorigenic differenti-
ated tumor cells. We isolated stem-like cells from five human
lung cancer cell lines harboring 3q26 copy number gains by
using established protocols (Eramo et al., 2008; Justilien et al.,
2012): H1299, H1703, ChagoK1, H520, and H1869. H1299,
H1703, and ChagoK1 grew as cell spheres (oncospheres) that
exhibit many stem-like properties (Figure 1A). First, when
returned to adherent culture, oncosphere cells redifferentiated
and acquired morphology comparable to parental cells (Fig-
ure 1A). Second, oncosphere cultures expressed elevated
mRNA for genes associated with a stem-like phenotype
including SOX2, OCT3/4, NANOG, ALDHA1, PROM1/CD133,
and MMP10 that was lost upon redifferentiation (Figure 1B).
Third, single oncosphere cells clonally expand with high effi-
ciency (H1703 cells, 91/98 cells [93%]; ChagoK1 cells, 41/44
cells [93%]; and H1299 cells, 125/138 cells [91%]) (Figure 1C).
Fourth, oncosphere cultures exhibited enhanced soft agar
growth, a property lost upon redifferentiation (Figure 1D). Similar
results were obtained in H520 and H1869 LSCC cells (Figures
S1A–S1D available online). Finally, oncospheres displayed
enhanced tumorigenic potential in vivo. Limiting dilution showed
that implantation of as few as 10,000 H1299 oncosphere cells
into the lungs of immune-deficient mice resulted in efficient
tumor take (5/5), but only occasional tumor take in parental cells
(1/5) (Figure 1Ee). A similar increase in tumor take was observed
in H520 oncospheres compared with parental H520 cells (Fig-
ure S1E). Oncosphere cells developed larger tumors than
parental cells and routinely produced lesions in the contralateral
lung, whereas parental cells did not. Oncosphere-derived
tumors exhibit morphology similar to parental cell tumors
(Figure 1Ed), and these tumors express SOX2, OCT3/4, NANOG,
ALDHA1, CD133, and MMP10 levels similar to that of parental
cells, indicating the ability of oncosphere cells to differentiate
in vivo (Figure S1). Finally, H1299 oncosphere cells efficiently
generate tumors of similar morphology through three serial
passages in mice (data not shown).
PKCi Maintains Oncospheres by Activating a Cell-
Autonomous Hh Signaling Axis
PKCi is necessary for transformation and expansion of bronchio-
alveolar stem cells (BASCs), putative tumor-initiating cells in(shown) or no identifiable tumor. The 403magnification reveals the similar morph
formation in limiting dilutions of H1299 oncosphere and parental cells (e). Quantifi
SEM, n = 5; *p < 0.05 versus parental cells (f).
See also Figure S1.
CKras-mediated lung tumorigenesis (Regala et al., 2009). Interest-
ingly, MMP10, a transcriptional target of PKCi in lung cancer
cells (Frederick et al., 2008) and transformed BASCs (Regala
et al., 2009), is induced in oncospheres (Figure 1B; Figure S1),
suggesting that PKCi is activated in these cells. Indeed, onco-
spheres exhibit an increase in T410 PKCi phosphorylation (Fig-
ure S2), an event associated with PKCi activity (Baldwin et al.,
2008; Desai et al., 2011; Le Good et al., 1998; Standaert et al.,
1999). PKCi RNA interference (RNAi) severely impaired soft
agar growth and clonal expansion of H1703, ChagoK1, and
H1299 oncospheres (Figures 2A and 2B), indicating that PKCi
is required for a stem-like phenotype. Similar results were
obtained in H520 and H1869 cells (Figure S2).
To identify PKCi-regulated pathways, we conducted total
RNA sequencing on nontarget (NT) and PKCi RNAi parental
and oncospheres from H1703, ChagoK1, and H1299 cells to
identify genes up- or downregulated in all three oncosphere lines
in a PKCi-dependent manner (Tables S1 and S2). We then used
MetaCore pathway analysis to determine whether PKCi regu-
lates three main pathways associated with stem maintenance:
Wnt, Hh, and Notch. Results revealed that PKCi significantly
regulates Hh (p = 0.025) but not Wnt (p = 0.091) or Notch (p =
0.354), suggesting a role for PKCi-dependent Hh signaling in
oncospheres. Hh components Hedgehog acyltransferase
(HHAT), ADRBK1, CDK19, and GLI1 were identified as PKCi
regulated (raw gene counts are given in Table S3; Hh signaling
components are listed in Table S4; and the RNA-seq data are
available in the Gene Expression Omnibus [GEO] database
[http://www.ncbi.nlm.nih.gov/gds] under the accession number
GSE48599), and these genes were validated by quantitative (q)
PCR in H1703 and H1299 oncospheres (Figure 2C).
Our data suggest that PKCi regulates Hh pathway activity to
stimulate oncosphere growth. Consistent with this notion, aura-
nofin, an antiarthritic gold salt that selectively inhibits PKCi
signaling (Erdogan et al., 2006; Stallings-Mann et al., 2006;
Wang et al., 2013), led to dose-dependent inhibition of onco-
sphere proliferation, with half maximal inhibitory concentration
values (IC50s) of 0.5–2.0 mM, and a significant decrease in
HHAT and Gli1 expression (Figure S2). Similarly, the Smooth-
ened (SMO) inhibitor LDE225 induced dose-dependent inhibi-
tion of oncosphere proliferation, with IC50s in the 10–40 nM
range, consistent with the submicromolar IC50 for SMO inhibition
(Buonamici et al., 2010) (Figure 2D). Interestingly, parental cells
were much less sensitive to LDE225 (IC50s > 5 mM; well above
the IC50 for SMO inhibition) (Figure 2D), consistent with reports
that lung progenitor/stem cells exhibit Hh-dependent prolifera-
tion, whereas differentiated NSCLC cells do not (Watkins et al.,
2003). Interestingly, oncospheres from LAC cell lines (A549,
H358, and H1437) are not sensitive to LDE225 (IC50s > 10 mM),
suggesting that Hh signaling is not required for LAC onco-
spheres (Figure S2). Furthermore, neither HHAT nor GLI1 is
induced in LAC oncospheres, and PKCi knockdown (KD) does
not affect expression of these genes (Figure S2), suggesting
that the PKCi-Hh signaling axis is not operative in LAC.ology of oncosphere- and parental cell-derived tumors (d). Incidence of tumor
cation of tumor growth by in vivo imaging system (IVIS). Data represent mean ±
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Figure 2. PKCi Is Required for Maintenance of a Stem-like Phenotype in Oncosphere Cells
(A) Effect of RNAi-mediated PKCi KD (immunoblot) on anchorage-independent growth of H1703, H1299, and ChagoK1 oncospheres. Results are expressed
relative to NT RNAi control cells ± SEM, n = 5; *p < 0.001. Results are representative of three independent experiments.
(B) Oncosphere size expressed as mean diameter in micrometers ± SEM, n = 98 (H1703), 138 (H1299), and 44 (ChagoK1). *p < 2 3 108.
(C) qPCR for HHAT, GLI1, ADRBK1, and CDK19. Results are expressed as fold NT parental cells ± SEM, n = 3; *p < 0.05 compared with NT parental. Results are
representative of three independent experiments.
(D) Effect of SMO inhibitor LDE225 on H1703, H1299, and ChagoK1 oncosphere (Onco.) and parental cell (Par.) proliferation. Results expressed as percentage of
DMSO control ± SEM, n = 6. Results are representative of three independent experiments.
See also Figure S2 and Tables S1, S2, and S3.
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PKCi and SOX2 Maintain Lung Cancer Stem-like CellsHHAT catalyzes a critical step in Hh ligand processing and
can initiate Hh signaling, and GLI1 is a major transcriptional
effector of Hh signaling. Therefore, we assessed the effect of
genetic inhibition of HHAT and GLI1 on stem-like behavior.
HHAT or GLI1 RNAi (Figures 3A and 3B) significantly inhibited
clonal expansion and soft agar growth of H1299 oncospheres
(Figures 3C and 3D). Similar results were observed in H1703,
ChagoK1, H520, and H1869 oncospheres (Figures S3A–S3D).
Results were validated by reconstitution using the small-mole-
cule Hh agonist Hh-Ag1.5. PKCi, HHAT, and GLI1 RNAi signifi-142 Cancer Cell 25, 139–151, February 10, 2014 ª2014 Elsevier Inc.cantly inhibited (Figure 3E) and Hh-Ag1.5 rescued oncosphere
growth in HHAT KD cells, but not PKCi or GLI1 KD cells
(Figure 3E). These results are expected because HHAT acts up-
stream of ligand, PKCi modulates Hh components both up-
stream (i.e., HHAT) and downstream (i.e., GLI1, ADRBK1, and
CDK19) of ligand, and GLI1 activates Hh-mediated transcription
downstream of ligand. Because PKCi regulates HHAT, an
enzyme required for sonic Hedgehog (SHH) palmitoylation, we
assessed the effect of PKCi and HHAT KD on palmitolyated
SHH production using the palmitic acid analog u-alkynyl
Figure 3. Oncosphere Growth Requires a PKCi-Dependent Hh Signaling Axis
(A and B) RNAi-mediated KD of HHAT (A) and GLI1 (B) in H1299 oncospheres expressed as fold of NT RNAi control ± SEM, n = 3; *p < 0.0005 compared with NT
control.
(C) Effect of HHAT or GLI1 RNAi on clonal expansion expressed as oncosphere diameter in micrometers ± SEM, nR 15 per RNAi sample; *p < 1.03 106. Data
are representative of three independent experiments.
(D) Soft agar growth expressed relative to NT RNAi control cells ± SEM, n = 5; *p < 0.003. Data are representative of three independent experiments.
(E) NT, PKCi, HHAT, and GLI1 oncospheres were treated with the indicated amounts of Hh-Ag1.5, a selective Hh agonist, and cell proliferation was assessed by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) at 5 days. Results are expressed as percentage of NT DMSO control ± SEM, n = 6.
(F) Detection of palmitoylated SHH in oncospheres. Parental (P) and oncosphere (O) NT, PKCi, and HHAT RNAi cultures expressing FLAG-SHH were meta-
bolically labeled with u-alkynyl-palmitate (C16), and palmitoylated SHH (palm SHH) and total SHH were detected as described in Experimental Procedures.
(G) Oncosphere growth as lung orthotopic tumors. NT parental and NT, PKCi, HHAT, and GLI1 RNAi oncosphere tumor growth was monitored by biolumi-
nescence detected by IVIS imaging. Data are presented as total flux in photons per second ± SEM, n = 10 per group except for PKCi, where n = 9; *p < 0.05
significantly different from NT RNAi oncosphere tumors.
See also Figure S3.
Cancer Cell
PKCi and SOX2 Maintain Lung Cancer Stem-like Cellspalmitate as described previously (Yap et al., 2010). Meta-
bolically labeled FLAG-SHH was immunoprecipitated with anti-
FLAG antibody, derivatized with azido-biotin using CLICK
chemistry, and palmitoylated SHH was detected by immunoblot
analysis using horseradish-NeutrAvidin (Figure 3F). NT H1299
oncospheres produce more palmitoylated SHH than NT parental
cells, and both PKCi and HHAT KD oncospheres exhibit a strik-
ing decrease in palmitoylated SHH. Similar results were obtained
in H1703 cells (Figure S3E). Thus, oncospheres use a PKCi-
dependent cell-autonomous Hh signaling pathway to maintain
their stem-like phenotype.
To assess the importance of PKCi-Hh signaling in oncosphere
behavior in vivo, we determined the ability of NT, PKCi, HHAT,
and GLI1 RNAi oncospheres, and NT parental cells, to initiate
lung orthotopic tumors in immune-deficient mice. As expected,
H1299 NT RNAi oncospheres exhibited an increased tumor
take rate (10/10 versus 2/10 mice for NT parental cells) andCdeveloped significantly larger tumors than NT RNAi parental
cells (Figure 3G). PKCi, HHAT, and GLI1 RNAi oncospheres
showed a decreased take rate (1/9, 0/10, and 1/10, respectively)
and failed to produce large tumors (Figure 3G). These data indi-
cate that cell-autonomous, PKCi-dependent Hh signaling is crit-
ical for the tumorigenic growth of oncospheres in vivo.
PKCi can phosphorylate Gli1 and activate its transcriptional
activity, and Gli1 can regulate PKCi expression, in basal cell
carcinoma cells (Atwood et al., 2013). Thus, we assessed Gli1
phosphorylation status in NT and PKCi KD oncospheres (Fig-
ure S3F). We observed a decrease in phospho-(p)Ser/Thr Gli1
commensurate with the decrease in total Gli1 in PKCi KD cells.
When normalized to total Gli1, no appreciable change in Gli1
phosphorylation was observed, indicating that the PKCi-Hh
signaling axis described here is distinct from that reported in
basal cell carcinoma (Figure S3F). Furthermore, neither HHAT
nor Gli1 RNAi affected PKCimRNA abundance in oncospheres,ancer Cell 25, 139–151, February 10, 2014 ª2014 Elsevier Inc. 143
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PKCi and SOX2 Maintain Lung Cancer Stem-like Cellsindicating that PKCi is not a target of Hh-Gli1 signaling in lung
cancer stem-like cells (Figure S3G).
PKCi Regulates SOX2-Mediated HHAT Expression in
Oncospheres
PRKCI is amplified as part of a 3q26 amplicon that drives PKCi
expression in LSCC tumors, leading us to explore other possible
genetic regulators residing on the 3q26 amplicon. SOX2, an
SRY-related high mobility group domain (HMG)-box (Sox) tran-
scription factor and master regulator of stem cell maintenance
(Sarkar and Hochedlinger, 2013), is consistently induced in our
oncosphere cultures (Figure 1B; Figure S1). SOX2 is an onco-
gene in LSCC (Bass et al., 2009), and it can maintain cancer
stem cells (Basu-Roy et al., 2012; Ikushima et al., 2011; Tian
et al., 2012). SOX2 RNAi (Figure 4A) significantly inhibited clonal
expansion and anchorage-independent growth of H1299 onco-
spheres (Figures 4B and 4C), indicating a key role for SOX2 in
these cells. Similar results were obtained in H1703, H520, and
H1869 oncospheres (Figure S4).
Chromatin immunoprecipitation (ChIP) sequencing analysis
of SOX2 revealed that SOX2 can occupy the HHAT promoter
and regulate HHAT expression in glioblastoma cells (Fang
et al., 2011). The proximal human HHAT promoter contains
seven potential SOX2 binding motifs (Figure 4D, inset). Interest-
ingly, SOX2 ChIP assays in NT and PKCi RNAi oncospheres
revealed SOX2 occupancy on the HHAT promoter in NT RNAi
cells and a significant decrease in occupancy in PKCi RNAi
cells without a change in SOX2 protein abundance (Figure 4D).
Furthermore, SOX2 KD (Figure 4E) led to a decrease in HHAT
mRNA and protein (Figure 4F). Similar results were obtained
in H1703 oncospheres (Figure S4). Thus, SOX2 regulates
HHAT promoter activity and expression by a PKCi-dependent
mechanism. Not surprisingly, growth of SOX2 RNAi onco-
spheres cannot be reconstituted by Hh agonist (Figure S4E),
indicating that SOX2 regulates genes in addition to HHAT
that are also required for maintenance of the stem-like
phenotype.
Given the functional link between PRKCI and SOX2, we
assessed whether these genes are coordinately amplified and
overexpressed in LSCC tumors. Interrogation of a LSCC data
set (178 cases) from The Cancer Genome Atlas (TCGA) revealed
that PRKCI and SOX2 are frequently coamplified and coordi-
nately overexpressed in primary LSCC tumors (Figure 4G). Anal-
ysis also revealed a strong positive correlation between PKCi
and SOX2 expression with HHAT and GLI1, two key Hh pathway
components regulated by PKCi in oncospheres harboring
PRKCI copy number gains (Figure 4H). SOX2 and HHAT expres-
sion also correlated in LSCC tumors, suggesting that SOX2
regulates HHAT expression in vivo (Table S5) and providing
evidence for the PKCi-SOX2-HHAT signaling axis in vivo. We
next assessed whether coordinate PRKCI and SOX2 amplifica-
tion may drive a ‘‘stem-like’’ genotype in primary LSCC tumors.
Airway basal cells exhibit stem-like properties (Hajj et al., 2007;
Hong et al., 2004; Rock et al., 2009) and are putative stem or
progenitor cells for LSCC (Ooi et al., 2010; Wistuba and Gazdar,
2006). Therefore, we tested for an association between PRKCI
and SOX2, and expression of a previously described 13-gene
airway basal stem cell signature (Shaykhiev et al., 2013). Analysis
revealed a strong positive correlation between PRKCI, SOX2,144 Cancer Cell 25, 139–151, February 10, 2014 ª2014 Elsevier Inc.and expression of 6 of 13 of the airway basal stem cell signature
genes (Table S6). Interestingly, this correlation was not observed
in primary LAC tumors, consistent with the proposed role of
basal cells as putative cells of origin for LSCC, but not LAC
(Wistuba and Gazdar, 2006).
Primary LSCC Cells Require PKCi, SOX2, and HHAT for
Oncosphere Formation and Proliferation
To assess whether PKCi-SOX2-Hh signaling regulates behavior
of primary LSCC tumors, we established oncosphere cultures
fromprimary LSCCs obtained from individuals undergoing tumor
resection. Similarly to established cell lines, primary LSCC tumor
cells readily grow as oncospheres in nonadherent stem cell
culture (Figure 5A). PKCi, SOX2, or HHAT RNAi led to efficient
KD of their respective target (Figure 5B). PKCi and SOX2 RNAi
cells also exhibited reduced HHAT and GLI1 expression,
whereas HHAT KD had no demonstrable effect on PKCi or
SOX2 expression (Figure 5B). PKCi, SOX2, and HHAT RNAi
similarly impaired oncosphere proliferation (Figure 5C). Further-
more, PKCi, SOX2, and HHAT RNAi cells produced small, disor-
ganized oncospheres (Figure 5D) exhibiting membrane blebbing
and intracellular vacuoles indicative of reduced cell viability
(Figure 5E, arrows). Thus, PKCi-SOX2-Hh signaling is important
for maintenance and survival of primary human LSCC stem-like
cells.
SOX2 Is a PKCi Substrate
Analysis of the SOX2 amino acid sequence indicated that SOX2
may serve as a substrate for atypical PKC. When purified re-
combinant human PKCi and recombinant human SOX2 were
incubated in a kinase reaction, robust incorporation of 32P from
ATP into SOX2was observed that is not observed in the absence
of PKCi (Figure 6A). To identify the site(s) phosphorylated by
PKCi, phosphorylated SOX2 was subjected to proteolytic diges-
tion and mass spectrometry (MS) analysis as described under
Experimental Procedures. MS analysis recovered peptides
encompassing all known phosphorylation sites on SOX2 and
revealed a single, previously uncharacterized phosphorylation
site, T118, that conforms to an atypical PKC consensus recogni-
tion motif (Figure 6B).
To assess the importance of T118 phosphorylation we first
introduced a silent mutation into a FLAG-tagged SOX2 cDNA
to render it resistant to SOX2 RNAi #2 and then mutagenized
T118 to either alanine (T118A) or aspartic acid (T118D) to elim-
inate or mimic T118 phosphorylation. Immunoblot analysis of
H1299 oncospheres stably transfected with wild-type (WT)-
SOX2, T118A-SOX2, T118D-SOX2, or empty control vector,
followed by SOX2 RNAi, revealed efficient loss of endogenous
SOX2 and expression of similar levels of WT- and T118-SOX2
mutants (Figure 6C). SOX2 RNAi oncospheres expressing
control vector showed reduced HHAT and GLI1 expression
as expected (Figure 6D). In contrast, expression of exogenous
WT- or T118D-SOX2 significantly restored HHAT and GLI1
expression in SOX2 RNAi cells, whereas T118A-SOX2 did not
(Figure 6D). As expected, SOX2 RNAi cells expressing empty
control vector showed impaired clonal expansion and soft
agar growth (Figures 6E and 6F). Expression of WT- or
T118D-SOX2 significantly reconstituted clonal expansion and
soft agar growth in SOX2 RNAi oncospheres, whereas
Figure 4. PKCi Regulates HHAT Expression through Control of SOX2 Occupancy of the HHAT Promoter
(A) RNAi-mediated KD of SOX2 in H1299 oncospheres. Results are expressed as percentage of NT control ± SEM, n = 3; *p < 0.05.
(B) Clonal expansion expressed as oncosphere diameter in micrometers ± SEM, n R 22 per RNAi sample; p < 3.0 3 1014. Data are representative of three
independent experiments.
(C) Anchorage-independent growth relative to NT RNAi control cells ± SEM, n = 5; *p < 5.03 109. Results are representative of three independent experiments.
(D) ChIP analysis to assess SOX2 occupancy of the HHAT promoter. Schematic depicts the HHAT promoter region; the positions of ChIP probes used are
indicated as A and B. Consensus SOX2 binding sites are indicated by vertical slashes. Data are presented as percentage of input ± SEM, n = 3; *p < 0.00002, **p <
0.00003. Data are representative of two independent experiments. IgG, immunoglobulin G.
(E and F) Effect of SOX2 RNAi (E) on HHAT expression in oncosphere cells (F). Data are expressed relative to NT RNAi control cells ± SEM (*p < 0.0007) and are
representative of three independent experiments.
(G) PRKCI and SOX2 amplification (top) and overexpression (bottom) in primary LSCC tumors. Red bars, tumors with amplification (top) or overexpression
(bottom); blue bars, tumors with decreased expression; gray bars, tumors with no change in gene copy number (top) or expression (bottom).
(H) Analysis of PRKCI, SOX2, HHAT, and GLI1 expression in primary LSCC tumors. Primary LSCC tumors were force ranked on PRKCI expression and grouped
into top and bottom tertiles corresponding to high and low PRKCI expression, respectively. Box plots denote the expression of PRKCI, SOX2,HHAT, andGLI1 in
tumors expressing low PRKCI (low) and high PRKCI (high). Bars represent themedian, and boxes denote the 25%and 75% intervals; whiskers represent the 90%
confidence intervals.
See also Figure S4 and Tables S4 and S5.
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Figure 5. Primary LSCC Cells Require PRKCI, SOX2, and HHAT for Oncosphere Formation and Proliferation
(A) Phase contrast photomicrographs of oncospheres from three surgically resected primary LSCC tumors.
(B) qPCR analysis of PRKCI, SOX2, HHAT, and GLI1 expressed as percentage of NT RNAi control ± SEM, n = 3; *p < 0.02.
(C) Proliferation of oncospheres by MTT assay expressed as percentage of NT RNAi control ± SEM, n = 3; *p < 4.0 3 107.
(D) Clonal expansion of oncospheres. Results expressed as percentage of NT RNAi control ± SEM, n = 3; *p < 0.0002.
(E) Photomicrographs of NT, PRKCI, SOX2, and HHAT KD oncospheres. Arrows show membrane blebbing indicative of cell death. Results are representative of
three independent experiments.
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PKCi and SOX2 Maintain Lung Cancer Stem-like CellsT118A-SOX2 did not (Figures 6E and 6F). SOX2 ChIP assays
revealed reduced SOX2 occupancy of the HHAT promoter in
SOX2 RNAi oncospheres expressing empty control vector
that is significantly restored by expression of either WT- or
T118D-SOX2, but not T118A-SOX2 (Figure 6G). T118 resides
between the HMG domain and a consensus nuclear locali-
zation sequence (NLS) in SOX2, suggesting that T118 phos-146 Cancer Cell 25, 139–151, February 10, 2014 ª2014 Elsevier Inc.phorylation could affect SOX2 DNA binding, nuclear
localization, or both. Immunoblot analysis revealed that WT-,
T118A-, and T118D-SOX2 are predominantly nuclear (Fig-
ure 6G, immunoblots). Next, SOX2 RNAi oncospheres express-
ing WT-, T118A-, or T118D-SOX2 or control empty pCMV
vector were transfected with an HHAT promoter luciferase re-
porter (pGL4-HHAT-luc) and assessed for HHAT promoter
Figure 6. PKCi Directly Phosphorylates SOX2 at a Unique Site, T118, that Is Required for SOX2 Function
(A) Recombinant human SOX2 was incubated in kinase reaction buffer containing [32P]ATP in the absence or presence of recombinant PKCi. Phosphorylated
SOX2 was detected by autoradiography, and total SOX2 was detected by immunoblot analysis.
(B) Schematic of SOX2 protein structure. TAD, transactivation domain. MS analysis revealed a single PKCi-mediated phosphorylation site on SOX2 at T118 that
conforms to a consensus atypical PKC phosphorylation site motif (insert).
(C) Immunoblot analysis of H1299 oncospheres stably transduced with NT or SOX2 RNAi and then stably transfected with either empty vector (V) or vector
encoding WT-SOX2 (WT), T118A-SOX2 (T118A), or T118D-SOX2 (T118D) mutants.
(D) qPCR analysis for HHAT and GLI1 expressed relative to NT RNAi control cells ± SEM, n = 3; *p < 0.03.
(E) Clonal expansion expressed relative to NT RNAi control cells ± SEM, n > 20 per cell type; *p < 1.0 3 108.
(F) Soft agar growth expressed relative to NT RNAi control cells ± SEM, n = 5, *p < 4.0 3 105.
(G) Cellular localization and promoter occupancy of T118-SOX2 phosphorylation mutants. Immunoblot analysis of cytoplasmic and nuclear fractions for FLAG,
Lamins A/C, and MEK1 (immunoblots). Lamins A/C served as a marker of nuclei and MEK1 as a marker of cytoplasm. HHAT promoter occupancy (bar graph)
expressed as fold of IgG control ± SEM, n = 3; *p < 0.001. Results in (D)–(G) are representative of three independent experiments.
See also Figure S5.
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PKCi and SOX2 Maintain Lung Cancer Stem-like Cellsactivity (Figure S5). In all four cell lines tested, WT- and T118D-
SOX2 stimulated HHAT promoter activity, whereas T118A did
not. Thus, PKCi-mediated T118-SOX2 phosphorylation regu-Clates SOX2 occupancy and HHAT promoter activity to stimulate
HHAT expression, thereby driving a PKCi-Hh signaling axis in
LSCC oncospheres.ancer Cell 25, 139–151, February 10, 2014 ª2014 Elsevier Inc. 147
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Accumulating evidence supports the existence of tumor-initi-
ating or cancer stem cells in human lung tumors that possess
the capacity to self-renew, and differentiate into bulk tumor cells.
These cells drive tumor initiation, progression, and metastasis,
and they may contribute to relapse after chemotherapy. The
majority of cancer deaths are caused by tumor metastasis and
relapse, making these cells an attractive therapeutic target to
achieve lasting therapeutic responses. However, the molecular
mechanisms that drive the enhanced tumorigenic potential and
stem-like behavior of tumor-initiating cells are poorly under-
stood. We previously demonstrated that PKCi maintains a
transformed phenotype in NSCLC cells and is critical for tumor
initiation inmurine lung cancer models (Regala et al., 2009). Prkci
is required for tumor initiation and expansion of Kras-trans-
formed BASCs, putative lung cancer stem cells in murine LAC
models (Regala et al., 2009). Here, we show that PKCi plays a
vital and previously unrecognized role in maintenance of stem-
like cells isolated from human lung cancer cells harboring PRKCI
copy number gains, and primary LSCC tumors. We also define a
PKCi-SOX2-Hh signaling axis that drives the stem-like pheno-
type of these cells.
Aberrant Hh signaling has been implicated in the initiation and
progression of various cancer subtypes, including lung. In basal
cell carcinomas andmedulloblastomas, Hh signaling is activated
by tumor-specific mutations in the Hh pathway components
Patched, SMO, or Suppressor of Fused (Epstein, 2008; Kool
et al., 2008). Tumors without activating Hh mutations often use
paracrine Hh signaling involving Hh ligand produced by tumor-
associated stromal cells (Dierks et al., 2007; Tian et al., 2009;
Yauch et al., 2008). Finally, some cancer cells exhibit autocrine
Hh signaling, in which Hh ligand is produced and used by the
same or neighboring tumor cells (Bar et al., 2007; Berman
et al., 2003; Karhadkar et al., 2004; Stecca et al., 2007; Varnat
et al., 2009). Autocrine Hh signaling has been described in
SCLC and NSCLC (Park et al., 2011; Rodriguez-Blanco et al.,
2013; Watkins et al., 2003); however, the factors that regulate
and maintain autocrine Hh signaling are largely unknown. We
find that PKCi regulates autocrine Hh signaling in oncospheres
harboring PRKCI copy number gains, and we define a signaling
cascade in which PKCi regulates HHAT that catalyzes the rate-
limiting step in Hh ligand processing. Our finding that HHAT KD
inhibits clonal expansion that can be reconstituted with Hh
agonist provides compelling evidence for the importance of
this autocrine Hh signaling mechanism in LSCC stem cell main-
tenance. Finally, our finding that HHAT KD oncospheres fail to
generate tumors in vivo indicates that autocrine Hh signaling is
vital for tumor initiation.
SOX2 is an oncogene in human LSCC (Bass et al., 2009;
Hussenet et al., 2010; Yuan et al., 2010). Sox2 overexpression
in mouse lung leads to increased lung epithelial cell proliferation
and hyperplasia (Tompkins et al., 2011), whereas Sox2 deletion
in mouse bronchiolar Clara cells, a potential lung regional stem
cell, results in reduced cell proliferation and loss of airway differ-
entiation markers (Tompkins et al., 2009). SOX2 is required for
LSCC cell growth in vitro, and SOX2 overexpression in lung
epithelial cells induces migration, transformed growth, and tu-
mor formation in vivo (Hussenet et al., 2010). Consistent with148 Cancer Cell 25, 139–151, February 10, 2014 ª2014 Elsevier Inc.these findings, we demonstrate that SOX2 maintains the tumor-
igenic potential of human LSCC oncospheres. We also uncover
an unexpected link between SOX2 and Hh signaling that is medi-
ated by PKCi. Our findings are consistent with SOX2-mediated
regulation of SHH expression in neural stem cells (NSCs) (Favaro
et al., 2009) and provide a potential molecular mechanism for
SOX2-mediated Hh signaling in NSCs.
Phosphorylation can regulate Sox2 function in mouse embry-
onic stem cells (Jeong et al., 2010), and phosphoproteome
analysis has identified Ser249, Ser250, and Ser251 as potential
SOX2 phosphorylation sites (Van Hoof et al., 2009). However,
the potential role of SOX2 phosphorylation in human cancer cells
has not been investigated. We find that PKCi phosphorylates
SOX2 at on a previously uncharacterized site, T118. T118 phos-
phorylation regulates SOX2 binding to, and activity of, the HHAT
promoter. Our MS analysis, which interrogated all known SOX2
phosphorylation sites, detected pThr118 but no other sites in
LSCC oncospheres (data not shown). These data indicate that
T118 is a major SOX2 phosphorylation site, although we cannot
exclude the presence of other low-level phosphorylation sites.
Regardless, our functional data demonstrate the importance of
T118 phosphorylation in SOX2 function and stem-like behavior.
Chromosome 3q26 amplification is one of the most frequent
chromosomal alterations in human cancer and is found in a
majority of LSCC (Balsara et al., 1997; Brass et al., 1996), serous
ovarian (Sonoda et al., 1997; Sugita et al., 2000), cervical (Sugita
et al., 2000), head and neck (Snaddon et al., 2001), oral (Lin et al.,
2005), and esophageal tumors (Imoto et al., 2001). Interestingly,
a major susceptibility locus for chemically induced mouse LSCC
is syntenic with human 3q26 and includes Prkci and Sox2, sug-
gesting a role for coordinate genetic alteration of Prkci and Sox2
in mouse LSCC (Wang et al., 2004). In this regard, SOX2 over-
expression is only weakly transforming (Hussenet et al., 2010),
and PKCi overexpression is not sufficient alone to cause cellular
transformation (Fields laboratory, unpublished data), suggesting
that these oncogenic factors may act in concert to exhibit full
tumorigenic potential. Consistent with this idea, PRKCI and
SOX2 are frequently coamplified and coordinately over-
expressed in LSCC tumors, and these tumors appear to exhibit
active PKCi-SOX2-Hh signaling. Based on our data, we pro-
pose that in LSCC tumors, and possibly other lung cancer
subtypes harboring 3q26 amplification, PRKCI and SOX2 are
co-oncogenic drivers activated through a single genetic alter-
ation that cooperatively drives tumorigenesis by maintaining a
stem-like phenotype through activation of a PKCi-SOX2-Hh
signaling axis. Interestingly, whereas each of the cell lines
analyzed here harbor PRKCI gene copy number gain and exhibit
PKCi-dependent Hh signaling, not all of these cell lines are
classified as LSCC. Three cell lines are classified histologically
as LSCC (H1703, H520, and H1869), whereas ChagoK1 and
H1299 cells are classified as bronchiogenic carcinoma
and LCLC, respectively, suggesting that PKCi-SOX2-HHAT
signaling may be operative in lung tumor types other than
LSCC that harbor PRKCI gene copy number gain. Given the
prevalence of chromosome 3q26 amplification in human tumors,
further studies are warranted to determine whether the PKCi-
SOX2-Hh signaling axis elucidated here maintains a stem-like
phenotype in other major tumor types harboring these genetic
alterations.
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PKCi and SOX2 Maintain Lung Cancer Stem-like CellsFinally, our results have broad implications for development
of new therapeutic strategies to target LSCC stem-like cells.
SMO inhibitors are in clinical development, but their utility is
limited in tumors that acquire Hh mutations that confer resis-
tance. PKCi, which regulates the Hh pathway both upstream
and downstream of SMO, may serve as an alternative therapeu-
tic strategy for modulating Hh signaling in tumors harboring
such mutations. Our data also provide a rationale for combined
use of PKCi and Hh inhibitors for treatment of LSCC tumors.
Finally, selective HHAT inhibitors have recently been developed
(Petrova et al., 2013). Such inhibitors may exhibit particular
potency in tumors harboring chromosome 3q26 amplification
and commensurate activation of the autocrine PKCi-SOX2-
HHAT signaling axis described here.
EXPERIMENTAL PROCEDURES
Cell Lines, Reagents, and Antibodies
We used the following antibodies: PKCi (BD Biosciences); b-actin, SOX2,
GLI1, Lamins A/C, mitogen-activated kinase kinase 1 (MEK1), phospho-
atypical PKC Thr-403/410 (Cell Signaling Technology); HHAT (Abgent), pSer/
Thr (Abcam), SHH (Santa Cruz Biotechnology), and FLAG (Sigma). Auranofin
(Prometheus Pharmaceuticals) and LDE225 and Hh-Ag1.5 (Cellagen) were
diluted in dimethyl sulfate (Me2SO). Cells were treated at concentrations
indicated in the figures, and control cells received an equal volume of
Me2SO at 0.1% (v/v). H1703, H1299, H520, H1869, and ChagoK1 lung
carcinoma cell lines were obtained from American Type Culture Collection
and maintained in low passage culture as recommended. H1299 firefly lucif-
erase cells were established by transducing cells with retroviral firefly
luciferase.
Enrichment, Clonal Expansion, and Redifferentiation of Lung
Cancer Cell Exhibiting a Stem-like Phenotype
Oncospheres were enriched from H1703, H1299, H520, H1869, and ChagoK1
cells and from primary human LSCC tumors essentially as described previ-
ously (Eramo et al., 2008; Justilien et al., 2012). Human tumor tissues were
obtained under informed consent, and their collection was approved by the
Mayo Clinic Institutional Review Board. Experimental details are provided in
Supplemental Experimental Procedures.
Lentiviral RNAi Constructs, Cell Transduction, Plasmids,
Transfections, and Immunoblot Analysis
Lentiviral vectors containing small hairpin RNAi against human PKCi, HHAT,
GLI1, and SOX2 were obtained from Sigma and packaged into recombinant
lentiviruses as described previously (Frederick et al., 2008). The human
SOX2 cDNA was cloned into a FLAG mammalian expression vector (QIAGEN
catalog no. DAM-105) and rendered RNAi resistant by silent mutation to
disrupt the SOX2 RNAi #2 target site as described previously (Frederick
et al., 2008). GLI1 was immunoprecipitated from cell lysates using mouse
anti-GLI1 and Protein A/G agarose beads (Santa Cruz) according to manufac-
turer’s procedure. Phospho(S/T)-GLI1 was detected in GLI1 immunoprecipi-
tates by immunoblot analysis using pSer/Thr antibody. Detailed protocols
are provided in Supplemental Experimental Procedures.
Anchorage-Independent Growth and Orthotopic Implantation
Studies
Anchorage-independent growth was assessed as described previously (Justi-
lien et al., 2012). All animal procedures were approved by theMayo Clinic Insti-
tutional Animal Care and Use Committee. Experimental details are provided in
Supplemental Experimental Procedures.
Metabolic Labeling and Detection of Palmitoylated SHH
Metabolic labeling and detection of palmitoylated SHH was performed essen-
tially as described previously (Yap et al., 2010). Experimental details are
provided in Supplemental Experimental Procedures.CDeep Sequence Analysis of Lung Cancer Cell Transcriptomes
Deep sequencing analysis was performed essentially as described previously
(Kalari et al., 2012). Experimental details are provided in Supplemental Exper-
imental Procedures.
Analysis of TCGA Gene Expression Data
Data from TCGA were analyzed using cBIO software (http://www.cbioportal.
org/public-portal/) software to correlate gene amplifications and gene expres-
sion in 178 human LSCC and 129 LAC tumors. Gene count (reads per kilobase
per million) values for these tumors were rank ordered according to PRKCI
expression and the top and bottom third were compared for differential
expression of HHAT, SOX2, GLI1, and the 13 gene airway basal stem cell
gene signature (Shaykhiev et al., 2013).
In Vitro PKCi Kinase Assays
PKCi in vitro kinase assays were performed as described previously (Justilien
et al., 2011). Details are provided in Supplemental Experimental Procedures.
ChIP and Analysis
ChIPs were performed to assess SOX2 occupancy on the HHAT promoter as
described in Supplemental Experimental Procedures.
HHAT Promoter Cloning and Luciferase Assays
An 1 kB fragment of the proximal 50 promoter region of human HHAT was
cloned by PCR from genomic DNA from H1703 cells. The promoter was
purified, sequenced to validate a match with the Pub-Med database
(NM_001170564), and TA cloned into pGL4-luciferase reporter plasmid using
standard techniques. Luciferase assays were conducted as described in Sup-
plemental Experimental Procedures.
MS Analysis of SOX2 Phosphorylation
PKCi phosphorylated SOX2 or SOX2 immunoprecipitated from H1703 cells
was isolated and submitted to the Mayo Clinic Cancer Center Protein
Chemistry and Proteomics Shared Resource for proteolytic cleavage and
phosphorylation site analysis by MS. Details are provided in Supplemental
Experimental Procedures.
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